Outlook Therapeutics is trading 5.19% down at $0.61, with the September 28, 2026 decline coinciding with broad risk-off trading, not a confirmed company-specific catalyst. - The supplied market data show the S&P 500 down 0.65% and Nasdaq down 0.94%, amid rising oil prices and Treasury yields. - No new company-specific announcement explaining the move appeared in the company’s press-release listings; the latest listed items were dated September 11 and September 10.